Vaccine Development

Nov 11, 2017
BioPharm International
This article discusses the potential of using high-productivity membrane chromatography to achieve intensified and flexible virus manufacturing.
Nov 10, 2017
By BioPharm International Editors
The company expects to commercially launch the new vaccine in the US in the first quarter of 2018.
Nov 03, 2017
By BioPharm International Editors
The Human Vaccines Project has created the Universal Influenza Vaccine Initiative, a research program that will aim to understand the human immune system’s role in the development of universal influenza vaccines.
Oct 27, 2017
By BioPharm International Editors
The vaccine is approved for the prevention of shingles in adult patients aged 50 years and older.
Oct 26, 2017
By BioPharm International Editors
Inovio has reported results from a study with non-human primates that showed 100% effectiveness with a DNA vaccine the company is developing with the US Army.
Oct 20, 2017
By BioPharm International Editors
The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.
Oct 19, 2017
By BioPharm International Editors
The two companies announced their collaboration for the production and development of cancer vaccines.
Oct 16, 2017
By BioPharm International Editors
Through the support of the Japanese agency, Daiichi Sankyo intends to further develop its genetic vaccine platform focused around its new nucleic acid delivery technology.
Oct 16, 2017
By BioPharm International Editors
The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.
Oct 12, 2017
By BioPharm International Editors
The collaboration will focus on developing a novel and differentiated challenge model for respiratory syncytial virus.
native1_300x100
lorem ipsum